Key points are not available for this paper at this time.
This Viewpoint summarizes recommendations made in a 2017 Blueprint for Transparency at the US Food and Drug Administration developed to encourage increased public access to FDA analyses and regulatory decisions.
Sharfstein et al. (Mon,) studied this question.